Article info
PDFStomach
Original research
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
- Correspondence to Dr Shumei Song, Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; ssong{at}mdanderson.org; Dr Jaffer A Ajani, Department of GI Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA; jajani{at}mdanderson.org
Citation
Targeting cancer stem cells with a pan-BCL-2 inhibitor in preclinical and clinical settings in patients with gastroesophageal carcinoma
Publication history
- Received March 20, 2020
- Revised January 3, 2021
- Accepted January 5, 2021
- First published January 24, 2021.
Online issue publication
January 08, 2022
Article Versions
- Previous version (8 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.